Tianjin Dexiang Biotechnology Co., Ltd. (hereinafter referred to as "Dexbio") was established on December 16, 2011. Located in Binhai New Area, the first national comprehensive reform and innovation zone approved by the State Council, it is a key project for investment promotion in Tianjin Economic-Technological Development Area (TEDA). With a registered capital of 30 million RMB and a total project investment exceeding 100 million RMB, Dexbio is a high-tech enterprise integrating R&D, production, and sales in the field of in vitro diagnostics.

In 2012, Dexbio was recognized as a "Tianjin Science and Technology-Based SME" by the Tianjin Municipal Science and Technology Bureau. In 2016, the company was certified as a Tianjin High-Tech Enterprise and a National High-Tech Enterprise. It went on to receive accolades including "TEDA T echnology Top 50" and "TEDA Gazelle Enterprise" in 2017, the first prize in the Tianjin Innovation and Entrepreneurship Competition and designation as a "Trusted Medical Device Manufacturer" in 2018, and titles such as "Tianjin Gazelle Enterprise," "Strategic Emerging Industry Leader Enterprise," and "Tianjin Technology-Advanced Enterprise" in 2019.

In 2020, Dexbio was awarded the Second Prize in Tianjin's Science and Technology Progress Awards. In 2021, the company was recognized by the Ministry of Industry and Information Technology as a "Specialized, Refined,Distinctive, and Innovative Little Giant."

Dexbio focuses on the development and application of microfluidic technology, holding nearly 50 patents and a comprehensive product portfolio. The company has achieved significant breakthroughs in key areas, including column agglutination technology(CAT), platelet typing and antibody screening, microfluidic testing, antigen synthesis, and cell immobilization technologies.

Leveraging strong research capabilities and precise market positioning, Dexbio has successfully developed and launched a series of transfusion testing products. In 2014, the company developed blood type products based on dual-mediacolumn agglutination technology (using glass microbeads and gel), which earned recognition as a Major Project in Tianjin that year, offering fully automated solutions for safe blood transfusion. In 2016, Dexbio developed a platelet typing and antibody screening kit (also a Tianjin Major Project), featuring abroader antigen spectrum and enhanced accuracy, effectively reducing platelet transfusion inefficiencies.

Dexbio's independently developed microfluidic testing cards represent the next generation of column agglutination cards. By innovatively applying microfluidic technology to transfusion safety, the product holds independent intellectual property rights, with core patents covering reagents and instruments. These patents have been granted in China and the United States, with European patents pending. The company also developed the industry's first intelligent blood grouping system and automated blood typing pipeline, offering intelligent solutions for transfusion medicine. The industrialization project for the Microfluidic Intelligent Blood Grouping System earned the 2021 China Association ofInventions Innovation Award, solidifying the company's strong competitive edgein domestic and international markets.

Inaddition to independent R&D, Dexbio established a CDMO (Contract Development and Manufacturing Organization) intelligent manufacturing centerand an innovation acceleration center in Tianjin. These facilities serve scientists from universities, research institutes, and medical institutions, fostering collaboration between industry, academia, research, and medicine. Dexbio provides full-cycle services, including R&D, registration, production, industrialization, and market promotion, creating a new ecosystem for technological innovation and industrial integration. This initiative contributes to the rapid and sustained development of Tianjin's biopharmaceutical industry.

Dexbio's marketing network and technical support team cover over 30 provinces, municipalities, and autonomous regions across China. The company has established the "Dexbio Worry-Free Testing" service standard, providing standardized services and comprehensive solutions for trial use, installation, commissioning, and after-sales support to blood centers, medical institutions, and health check-up centers.

Corporate Philosophy: Pursuing Excellence, Striving for Perfection
Dexbio is dedicated to advancing the development and application of innovative technologies, building a new ecosystem with its innovation acceleration center, and driving the modernization and intelligent transformation of medical devices. Committed to delivering superior diagnostic solutions for patients, Dexbio aims to bring China's diagnostic technologies to the global stage.